NCT01018563View on ClinicalTrials.gov

An Open Label Extension Study of the Efficacy of MORAb-003

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 13, 2010

Primary Completion Date

March 5, 2013

Study Completion Date

March 5, 2013

Conditions
Epithelial Ovarian Cancer
Interventions
DRUG

MORAb-003

Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.

Trial Locations (3)

69120

Nationales Centrum fur Tumorerkrandungen, Heidelberg

78229

South Texas Oncology & Hematology, San Antonio

91911

Sharp Memorial Hospital, Chula Vista

Sponsors

Lead Sponsor

Morphotek
All Listed Sponsors
lead

Morphotek

INDUSTRY